Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06214221 · ClinicalTrials.gov registry record · NA
Using Signos mHealth Platform in Adults for Weight Management
A NA study of Weight Loss and Overweight and Obesity, sponsored by Signos.
- Active
- Registry status
- NA
- Development phase
- 380
- Enrollment target
- 5
- Study locations
NCT06214221: Active NA study of Weight Loss and Overweight and Obesity, sponsored by Signos.
NCT06214221 is a NA study of Weight Loss and Overweight and Obesity that is active but no longer recruiting, run by Signos. The registered enrollment target is 380 participants, below the 1,498-participant average among 116 other Weight Loss trials with a reported enrollment target (75% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06214221, a NA study of Weight Loss and Overweight and Obesity, is active but no longer recruiting, sponsored by Signos.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 380 participants
- Enrollment target
- 5
- Study locations
Study Summary
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools that help participants in the pursuit of weight change goals. The investigators hypothesize that the use of CGM data and targeted coaching and nutrition education will assist with weight optimization goals in the general (non-diabetic) population using the Signos mHealth platform, with associated health benefits.
Primary Outcome
Investigators will measure how many participants successfully reached their weight management goals by the end of 6 months. This 'Responder Rate' tells us the percentage of people in our study who effectively managed their weight using the methods we provided, whether it's through the Signos System or standard lifestyle education.
Conditions Studied
Interventions
- DEVICE Signos System
- OTHER Standard Lifestyle Education
Study Locations (5)
Arizona
- Helios Clinical Research (Phoenix) - Phoenix
California
- Diablo Clinical Research - Walnut Creek
Florida
- Segal Trials - North Miami
Texas
- Helios Clinical Research - Houston
Washington
- Seattle Clinical Research - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2024-01-02 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT06214221 still lists
NCT06214221 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, below the 1,498-participant average among 116 other Weight Loss trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Weight Loss appearing as the primary indexed condition, and to 2 interventions - of which Signos System is the first listed.
NCT06214221 lists 5 locations in 5 states (Arizona, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06214221 about?
NCT06214221 is a clinical study titled "Using Signos mHealth Platform in Adults for Weight Management". Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence and results from diet and exercise changes in individuals with obesity. M...
What is the current status of trial NCT06214221?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2024-01-02. Estimated completion is 2026-04-30.
What conditions does trial NCT06214221 study?
This clinical trial studies the following conditions: Weight Loss, Overweight and Obesity, Metabolic Syndrome.
What interventions are being tested in trial NCT06214221?
The interventions under investigation include: Signos System (DEVICE), Standard Lifestyle Education (OTHER).
Who is sponsoring clinical trial NCT06214221?
This trial is sponsored by Signos, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06214221 being conducted?
This trial has 5 study locations across Arizona, California, Florida, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Weight Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06214221's enrollment target sits among peer trials
380 13th of 116 higher than 104 of 116 other Weight Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Weight Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Metabolic Health, Bones and Nuts During Weight Loss in Adults
RECRUITING · NA
-
FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)
RECRUITING · NA
-
Exercise Effects on Adipose Tissue Structure and Function
RECRUITING · NA
-
Circadian Time Restricted Eating
RECRUITING · NA
-
Family COMIDA (Consumo de Opciones Más Ideales De Alimentos) (Eating More Ideal Food Options)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI